Background: Mifepristone is a steroid-based drug that blocks glucocorticoid and progesterone effects. It enhances uterine contractions and promotes cervical changes necessary for childbirth. This study evaluates how effective a single oral dose of mifepristone is for cervical preparation during labor induction in the third trimester, examining both mother and baby outcomes, along with any side effects.

Method: The study involved 120 women at full term (37-40 weeks) with unfavorable cervical scores (Bishop score <6). They were divided equally into two groups: 60 women received 200mg oral mifepristone (Study Group), while 60 received a placebo (Control Group). After 24 hours, cervical changes were evaluated using the Bishop’s score. Subsequently, 25μg misoprostol was given vaginally every 4 hours, up to 6 times, to start or strengthen labor. The study analyzed both maternal and fetal outcomes to assess the drug’s safety and effectiveness.

Results: Bishop score improvement was noted in 64% of participants. The study group showed faster progression from induction to delivery, with a notable 46% of patients not requiring any misoprostol after mifepristone treatment, suggesting mifepristone alone might suffice for future labor inductions. Neonatal intensive care admission rates were lower in the study group (4%) compared to the control group (12%).